In Vitro Antitumor Activity of Aloperine on Human Thyroid Cancer Cells through Caspase-Dependent Apoptosis

The global incidence of thyroid cancer, one of the most common endocrine malignancies, is especially high among women. Although most patients with thyroid cancers exhibit a good prognosis with standard treatment, there are no effective therapies for patients with anaplastic thyroid cancers or cancer...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 19; no. 1; p. 312
Main Authors Lee, Ying-Ray, Chen, Shu-Hsin, Lin, Ching-Yen, Chao, Wen-Ying, Lim, Yun-Ping, Yu, Hui-I, Lu, Chieh-Hsiang
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 21.01.2018
MDPI
Subjects
Antineoplastic Agents - pharmacology
Apoptosis
Apoptosis - drug effects
Biomarkers
Caspases - metabolism
Cell cycle
Cell Cycle - drug effects
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Transformation, Neoplastic - genetics
Cell Transformation, Neoplastic - metabolism
Flow Cytometry
Humans
Neuroendocrine tumors
Piperidines - pharmacology
Proto-Oncogene Proteins c-akt - metabolism
Signal Transduction - drug effects
Thyroid cancer
Thyroid Neoplasms - genetics
Thyroid Neoplasms - metabolism
Thyroid Neoplasms - pathology
apoptosis
thyroid cancer
aloperine
Online AccessGet full text

Cover

Abstract The global incidence of thyroid cancer, one of the most common endocrine malignancies, is especially high among women. Although most patients with thyroid cancers exhibit a good prognosis with standard treatment, there are no effective therapies for patients with anaplastic thyroid cancers or cancers that have reached an advanced or recurrent level. Therefore, it is important to develop highly effective compounds for treating such patients. Aloperine, a natural compound isolated from Sophora alopecuroides, has been reported to possess antioxidant, anti-inflammatory, anti-neuronal injury, anti-renal injury, antitumor, anti-allergic, and antiviral properties. In this study, we show that aloperine can inhibit cell growth in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers. Moreover, it could suppress in vitro tumorigenesis and promote cellular apoptosis. Further analysis demonstrated the involvement of caspase-dependent apoptosis, including intrinsic and/or extrinsic pathways, in aloperine-induced cellular apoptosis. However, cell cycle regulation was not detected with aloperine treatment. This study suggests the potential therapeutic use of aloperine in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers.
AbstractList The global incidence of thyroid cancer, one of the most common endocrine malignancies, is especially high among women. Although most patients with thyroid cancers exhibit a good prognosis with standard treatment, there are no effective therapies for patients with anaplastic thyroid cancers or cancers that have reached an advanced or recurrent level. Therefore, it is important to develop highly effective compounds for treating such patients. Aloperine, a natural compound isolated from Sophora alopecuroides, has been reported to possess antioxidant, anti-inflammatory, anti-neuronal injury, anti-renal injury, antitumor, anti-allergic, and antiviral properties. In this study, we show that aloperine can inhibit cell growth in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers. Moreover, it could suppress in vitro tumorigenesis and promote cellular apoptosis. Further analysis demonstrated the involvement of caspase-dependent apoptosis, including intrinsic and/or extrinsic pathways, in aloperine-induced cellular apoptosis. However, cell cycle regulation was not detected with aloperine treatment. This study suggests the potential therapeutic use of aloperine in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers.The global incidence of thyroid cancer, one of the most common endocrine malignancies, is especially high among women. Although most patients with thyroid cancers exhibit a good prognosis with standard treatment, there are no effective therapies for patients with anaplastic thyroid cancers or cancers that have reached an advanced or recurrent level. Therefore, it is important to develop highly effective compounds for treating such patients. Aloperine, a natural compound isolated from Sophora alopecuroides, has been reported to possess antioxidant, anti-inflammatory, anti-neuronal injury, anti-renal injury, antitumor, anti-allergic, and antiviral properties. In this study, we show that aloperine can inhibit cell growth in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers. Moreover, it could suppress in vitro tumorigenesis and promote cellular apoptosis. Further analysis demonstrated the involvement of caspase-dependent apoptosis, including intrinsic and/or extrinsic pathways, in aloperine-induced cellular apoptosis. However, cell cycle regulation was not detected with aloperine treatment. This study suggests the potential therapeutic use of aloperine in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers.
The global incidence of thyroid cancer, one of the most common endocrine malignancies, is especially high among women. Although most patients with thyroid cancers exhibit a good prognosis with standard treatment, there are no effective therapies for patients with anaplastic thyroid cancers or cancers that have reached an advanced or recurrent level. Therefore, it is important to develop highly effective compounds for treating such patients. Aloperine, a natural compound isolated from , has been reported to possess antioxidant, anti-inflammatory, anti-neuronal injury, anti-renal injury, antitumor, anti-allergic, and antiviral properties. In this study, we show that aloperine can inhibit cell growth in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers. Moreover, it could suppress in vitro tumorigenesis and promote cellular apoptosis. Further analysis demonstrated the involvement of caspase-dependent apoptosis, including intrinsic and/or extrinsic pathways, in aloperine-induced cellular apoptosis. However, cell cycle regulation was not detected with aloperine treatment. This study suggests the potential therapeutic use of aloperine in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers.
The global incidence of thyroid cancer, one of the most common endocrine malignancies, is especially high among women. Although most patients with thyroid cancers exhibit a good prognosis with standard treatment, there are no effective therapies for patients with anaplastic thyroid cancers or cancers that have reached an advanced or recurrent level. Therefore, it is important to develop highly effective compounds for treating such patients. Aloperine, a natural compound isolated from Sophora alopecuroides, has been reported to possess antioxidant, anti-inflammatory, anti-neuronal injury, anti-renal injury, antitumor, anti-allergic, and antiviral properties. In this study, we show that aloperine can inhibit cell growth in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers. Moreover, it could suppress in vitro tumorigenesis and promote cellular apoptosis. Further analysis demonstrated the involvement of caspase-dependent apoptosis, including intrinsic and/or extrinsic pathways, in aloperine-induced cellular apoptosis. However, cell cycle regulation was not detected with aloperine treatment. This study suggests the potential therapeutic use of aloperine in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers.
The global incidence of thyroid cancer, one of the most common endocrine malignancies, is especially high among women. Although most patients with thyroid cancers exhibit a good prognosis with standard treatment, there are no effective therapies for patients with anaplastic thyroid cancers or cancers that have reached an advanced or recurrent level. Therefore, it is important to develop highly effective compounds for treating such patients. Aloperine, a natural compound isolated from Sophora alopecuroides , has been reported to possess antioxidant, anti-inflammatory, anti-neuronal injury, anti-renal injury, antitumor, anti-allergic, and antiviral properties. In this study, we show that aloperine can inhibit cell growth in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers. Moreover, it could suppress in vitro tumorigenesis and promote cellular apoptosis. Further analysis demonstrated the involvement of caspase-dependent apoptosis, including intrinsic and/or extrinsic pathways, in aloperine-induced cellular apoptosis. However, cell cycle regulation was not detected with aloperine treatment. This study suggests the potential therapeutic use of aloperine in human anaplastic thyroid cancers and multidrug-resistant papillary thyroid cancers.
Author Lin, Ching-Yen
Chen, Shu-Hsin
Lim, Yun-Ping
Yu, Hui-I
Lee, Ying-Ray
Chao, Wen-Ying
Lu, Chieh-Hsiang
AuthorAffiliation 2 Department of Nursing, Min-Hwei College of Health Care Management, Tainan 736, Taiwan; april@mail.mhchcm.edu.tw
4 Division of Endocrinology and Metabolism, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi 600, Taiwan; 04490@cych.org.tw
5 Department of Biotechnology, Asia University, Taichung 404, Taiwan
1 Department of Medical Research, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi 600, Taiwan; yingray.lee@gmail.com (Y.-R.L.); cych10472@gmail.com (S.-H.C.); jouyuan22@gmail.com (C.-Y.L.)
3 Department of Pharmacy, College of Pharmacy, China Medical University, Taichung 404, Taiwan; limyp@mail.cmu.edu.tw
AuthorAffiliation_xml – name: 3 Department of Pharmacy, College of Pharmacy, China Medical University, Taichung 404, Taiwan; limyp@mail.cmu.edu.tw
– name: 5 Department of Biotechnology, Asia University, Taichung 404, Taiwan
– name: 2 Department of Nursing, Min-Hwei College of Health Care Management, Tainan 736, Taiwan; april@mail.mhchcm.edu.tw
– name: 4 Division of Endocrinology and Metabolism, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi 600, Taiwan; 04490@cych.org.tw
– name: 1 Department of Medical Research, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi 600, Taiwan; yingray.lee@gmail.com (Y.-R.L.); cych10472@gmail.com (S.-H.C.); jouyuan22@gmail.com (C.-Y.L.)
Author_xml – sequence: 1
  givenname: Ying-Ray
  orcidid: 0000-0002-0349-0960
  surname: Lee
  fullname: Lee, Ying-Ray
– sequence: 2
  givenname: Shu-Hsin
  surname: Chen
  fullname: Chen, Shu-Hsin
– sequence: 3
  givenname: Ching-Yen
  surname: Lin
  fullname: Lin, Ching-Yen
– sequence: 4
  givenname: Wen-Ying
  surname: Chao
  fullname: Chao, Wen-Ying
– sequence: 5
  givenname: Yun-Ping
  surname: Lim
  fullname: Lim, Yun-Ping
– sequence: 6
  givenname: Hui-I
  surname: Yu
  fullname: Yu, Hui-I
– sequence: 7
  givenname: Chieh-Hsiang
  surname: Lu
  fullname: Lu, Chieh-Hsiang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29361731$$D View this record in MEDLINE/PubMed
BookMark eNptkUtLJDEUhYM4-Bp3riXgxsXUmEcllWyEouehILjR2YZ0KmWnqUrKJCX0v580PuiRWeWS-93DOZxjsO-DtwCcYfSdUomu3HpMWCKMKCZ74AjXhFQI8WZ_Zz4ExymtESKUMHkADomkHDcUH4H1rYd_XI4Btj67PI8hwtZk9-LyBoYetkOYbHTewuDhzTxqDx9WmxhcBxfaGxvhwg5DgnkVw_y0Kp9p0slWP-xkfWd9hu0UphySS1_Bl14PyZ6-vSfg8dfPh8VNdXf_-3bR3lWmxiRXNV9aSbEUvaacUSQEkh0T_ZKxhtadEVIiTamlgkluOBa4512tedcTLmzf0BNw_ao7zcvRdqaYiHpQU3SjjhsVtFP_brxbqafwolgjOWG8CFy-CcTwPNuU1eiSKTG1t2FOChcHgmEuWUEvPqHrMEdf4imCkSSSYL4VPN919GHlvYYCfHsFTAwpRdt_IBipbctqt-WCk0-4cVlnF7Z53PD_o7-JiqsW
CitedBy_id crossref_primary_10_3390_ijms21124218
crossref_primary_10_3892_mmr_2021_12418
crossref_primary_10_2147_OTT_S260215
crossref_primary_10_3390_cancers13174266
crossref_primary_10_3390_ijms20215315
crossref_primary_10_1016_j_phymed_2019_152843
crossref_primary_10_1111_cbdd_14444
crossref_primary_10_1080_26895293_2021_1918583
crossref_primary_10_1186_s43556_023_00155_x
crossref_primary_10_3389_fphar_2020_538137
crossref_primary_10_3390_biomedicines10040905
crossref_primary_10_1111_jcmm_16265
crossref_primary_10_1139_bcb_2021_0251
crossref_primary_10_1016_j_biopha_2018_09_008
crossref_primary_10_1016_j_jep_2020_112775
crossref_primary_10_2174_1389557521666210831155426
crossref_primary_10_1007_s00432_020_03157_2
crossref_primary_10_1016_j_fitote_2020_104640
crossref_primary_10_1016_j_jchromb_2021_122671
crossref_primary_10_3892_or_2022_8368
crossref_primary_10_3390_ijms24098048
crossref_primary_10_3390_cells11081326
crossref_primary_10_1021_acsomega_3c02179
crossref_primary_10_62347_DNTG2917
crossref_primary_10_1016_j_jep_2019_112172
crossref_primary_10_3390_ijms25105395
crossref_primary_10_7717_peerj_7652
crossref_primary_10_3389_fsurg_2020_00043
crossref_primary_10_1016_j_ejmech_2019_111972
crossref_primary_10_1016_j_tice_2021_101706
crossref_primary_10_2174_0929866527666200320094313
Cites_doi 10.3322/caac.21387
10.1016/j.ejphar.2009.12.007
10.3892/ijmm.2014.1718
10.1016/j.trecan.2017.04.002
10.1371/journal.pone.0158587
10.1016/j.phrs.2016.11.038
10.21873/anticanres.11428
10.2119/molmed.2015.00056
10.1021/jf103581r
10.1111/j.1742-7843.2010.00653.x
10.1021/acsmedchemlett.5b00339
10.1007/s11418-015-0928-2
10.1007/s11095-012-0727-3
10.1186/s13045-015-0120-x
10.1038/sj.onc.1207115
10.3892/etm.2016.3962
10.3389/fendo.2015.00188
10.1016/j.biopha.2017.02.033
10.3892/or.2017.5732
ContentType Journal Article
Copyright 2018. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2018 by the authors. 2018
Copyright_xml – notice: 2018. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2018 by the authors. 2018
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
5PM
DOI 10.3390/ijms19010312
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Publicly Available Content Database

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1422-0067
ExternalDocumentID PMC5796256
29361731
10_3390_ijms19010312
Genre Journal Article
GroupedDBID ---
29J
2WC
53G
5GY
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
8G5
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
AEAQA
AENEX
AFKRA
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
DWQXO
E3Z
EBD
EBS
EJD
ESX
F5P
FRP
FYUFA
GNUQQ
GUQSH
GX1
HH5
HMCUK
HYE
IAO
IHR
IPNFZ
ITC
KQ8
LK8
M1P
M2O
M48
MODMG
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RIG
RNS
RPM
TR2
TUS
UKHRP
~8M
3V.
ABJCF
BBNVY
BHPHI
CGR
CUY
CVF
ECM
EIF
GROUPED_DOAJ
HCIFZ
KB.
M7P
M~E
NPM
PDBOC
7XB
8FK
K9.
MBDVC
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
Q9U
7X8
5PM
ID FETCH-LOGICAL-c412t-46be93198fa365308809d58fb55734dc8990a33e38596c6181f6d4a6df268ef73
IEDL.DBID M48
ISSN 1422-0067
1661-6596
IngestDate Thu Aug 21 14:10:02 EDT 2025
Tue Aug 05 10:11:03 EDT 2025
Fri Jul 25 20:41:10 EDT 2025
Wed Feb 19 02:42:12 EST 2025
Tue Jul 01 01:45:05 EDT 2025
Thu Apr 24 22:58:26 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords apoptosis
thyroid cancer
aloperine
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c412t-46be93198fa365308809d58fb55734dc8990a33e38596c6181f6d4a6df268ef73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0349-0960
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/ijms19010312
PMID 29361731
PQID 2109292166
PQPubID 2032341
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5796256
proquest_miscellaneous_1990851695
proquest_journals_2109292166
pubmed_primary_29361731
crossref_primary_10_3390_ijms19010312
crossref_citationtrail_10_3390_ijms19010312
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-01-21
PublicationDateYYYYMMDD 2018-01-21
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-21
  day: 21
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle International journal of molecular sciences
PublicationTitleAlternate Int J Mol Sci
PublicationYear 2018
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Yi (ref_17) 2017; 32
Hua (ref_19) 2012; 29
Lu (ref_18) 2017; 115
Dang (ref_10) 2016; 7
Thibault (ref_16) 2017; 3
Ren (ref_11) 2017; 13
ref_13
Franke (ref_14) 2003; 22
ref_20
Hu (ref_9) 2015; 21
Ma (ref_7) 2015; 69
Zhou (ref_3) 1989; 10
Yuan (ref_4) 2010; 629
Lin (ref_6) 2011; 59
Wang (ref_8) 2015; 8
ref_15
Zhang (ref_2) 2014; 33
Shi (ref_21) 2017; 37
Lin (ref_5) 2011; 108
Siegel (ref_1) 2017; 67
Wu (ref_12) 2017; 89
20006963 - Eur J Pharmacol. 2010 Mar 10;629(1-3):147-52
2533795 - Zhongguo Yao Li Xue Bao. 1989 Jul;10(4):360-5
21159130 - Basic Clin Pharmacol Toxicol. 2011 May;108(5):304-9
28718419 - Trends Cancer. 2017 Jun;3(6):454-469
28314276 - Anticancer Res. 2017 Mar;37(3):1149-1159
24682388 - Int J Mol Med. 2014 Jun;33(6):1613-20
28622037 - Cancer Biother Radiopharm. 2017 Jun;32(5):176-183
26793165 - Front Endocrinol (Lausanne). 2016 Jan 11;6:188
26552059 - Mol Med. 2015 Nov 03;:null
28055103 - CA Cancer J Clin. 2017 Jan;67(1):7-30
27385117 - PLoS One. 2016 Jul 06;11(7):e0158587
25886453 - J Hematol Oncol. 2015 Mar 15;8:26
28123508 - Exp Ther Med. 2017 Jan;13(1):315-320
21155568 - J Agric Food Chem. 2011 Jan 12;59(1):184-92
26142710 - J Nat Med. 2015 Oct;69(4):575-83
22477067 - Pharm Res. 2012 Jul;29(7):1990-2005
14663477 - Oncogene. 2003 Dec 8;22(56):8983-98
28627629 - Oncol Rep. 2017 Jun 19;:null
27940017 - Pharmacol Res. 2017 Jan;115:288-298
28262616 - Biomed Pharmacother. 2017 May;89:632-641
26985308 - ACS Med Chem Lett. 2016 Jan 09;7(3):240-4
References_xml – volume: 67
  start-page: 7
  year: 2017
  ident: ref_1
  article-title: Cancer Statistics
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21387
– volume: 629
  start-page: 147
  year: 2010
  ident: ref_4
  article-title: Effects and mechanisms of aloperine on 2,4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2009.12.007
– volume: 32
  start-page: 176
  year: 2017
  ident: ref_17
  article-title: Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer
  publication-title: Cancer Biother. Radiopharm.
– volume: 33
  start-page: 1613
  year: 2014
  ident: ref_2
  article-title: Aloperine induces G2/M phase cell cycle arrest and apoptosis in HCT116 human colon cancer cells
  publication-title: Int. J. Mol. Med.
  doi: 10.3892/ijmm.2014.1718
– volume: 3
  start-page: 454
  year: 2017
  ident: ref_16
  article-title: Targeting PI3K Signaling in Combination Cancer Therapy
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2017.04.002
– ident: ref_20
  doi: 10.1371/journal.pone.0158587
– volume: 115
  start-page: 288
  year: 2017
  ident: ref_18
  article-title: Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2016.11.038
– volume: 37
  start-page: 1149
  year: 2017
  ident: ref_21
  article-title: Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells
  publication-title: Anticancer Res.
  doi: 10.21873/anticanres.11428
– volume: 10
  start-page: 360
  year: 1989
  ident: ref_3
  article-title: Anti-inflammatory and anti-allergic action of aloperine
  publication-title: Acta Pharmacol. Sin.
– volume: 21
  start-page: 912
  year: 2015
  ident: ref_9
  article-title: Aloperine protects mice against ischemia reperfusion (IR)-induced renal injury by regulating PI3K/AKT/mTOR signaling and AP-1 activity
  publication-title: Mol. Med.
  doi: 10.2119/molmed.2015.00056
– volume: 59
  start-page: 184
  year: 2011
  ident: ref_6
  article-title: Five bitter compounds display different anti-inflammatory effects through modulating cytokine secretion using mouse primary splenocytes in vitro
  publication-title: J. Agric. Food Chem.
  doi: 10.1021/jf103581r
– volume: 108
  start-page: 304
  year: 2011
  ident: ref_5
  article-title: In vitro anti-tumour activities of quinolizidine alkaloids derived from Sophora flavescens Ait
  publication-title: Basic Clin. Pharmacol. Toxicol.
  doi: 10.1111/j.1742-7843.2010.00653.x
– volume: 7
  start-page: 240
  year: 2016
  ident: ref_10
  article-title: Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/acsmedchemlett.5b00339
– volume: 69
  start-page: 575
  year: 2015
  ident: ref_7
  article-title: Protective effects of aloperine on neonatal rat primary cultured hippocampal neurons injured by oxygen-glucose deprivation and reperfusion
  publication-title: J. Nat. Med.
  doi: 10.1007/s11418-015-0928-2
– volume: 29
  start-page: 1990
  year: 2012
  ident: ref_19
  article-title: Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-012-0727-3
– volume: 8
  start-page: 26
  year: 2015
  ident: ref_8
  article-title: Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-015-0120-x
– volume: 22
  start-page: 8983
  year: 2003
  ident: ref_14
  article-title: PI3K/Akt and apoptosis: Size matters
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207115
– volume: 13
  start-page: 315
  year: 2017
  ident: ref_11
  article-title: Aloperine attenuates hydrogen peroxide-induced injury via anti-apoptotic activity and suppression of the nuclear factor-κB signaling pathway
  publication-title: Exp. Ther. Med.
  doi: 10.3892/etm.2016.3962
– ident: ref_15
  doi: 10.3389/fendo.2015.00188
– volume: 89
  start-page: 632
  year: 2017
  ident: ref_12
  article-title: Protective effects of aloperine on monocrotaline-induced pulmonary hypertension in rats
  publication-title: Biomed. Pharmacother. Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2017.02.033
– ident: ref_13
  doi: 10.3892/or.2017.5732
– reference: 27940017 - Pharmacol Res. 2017 Jan;115:288-298
– reference: 26985308 - ACS Med Chem Lett. 2016 Jan 09;7(3):240-4
– reference: 22477067 - Pharm Res. 2012 Jul;29(7):1990-2005
– reference: 25886453 - J Hematol Oncol. 2015 Mar 15;8:26
– reference: 27385117 - PLoS One. 2016 Jul 06;11(7):e0158587
– reference: 24682388 - Int J Mol Med. 2014 Jun;33(6):1613-20
– reference: 2533795 - Zhongguo Yao Li Xue Bao. 1989 Jul;10(4):360-5
– reference: 28622037 - Cancer Biother Radiopharm. 2017 Jun;32(5):176-183
– reference: 14663477 - Oncogene. 2003 Dec 8;22(56):8983-98
– reference: 26552059 - Mol Med. 2015 Nov 03;:null
– reference: 28314276 - Anticancer Res. 2017 Mar;37(3):1149-1159
– reference: 28718419 - Trends Cancer. 2017 Jun;3(6):454-469
– reference: 21155568 - J Agric Food Chem. 2011 Jan 12;59(1):184-92
– reference: 21159130 - Basic Clin Pharmacol Toxicol. 2011 May;108(5):304-9
– reference: 20006963 - Eur J Pharmacol. 2010 Mar 10;629(1-3):147-52
– reference: 28123508 - Exp Ther Med. 2017 Jan;13(1):315-320
– reference: 28262616 - Biomed Pharmacother. 2017 May;89:632-641
– reference: 26142710 - J Nat Med. 2015 Oct;69(4):575-83
– reference: 26793165 - Front Endocrinol (Lausanne). 2016 Jan 11;6:188
– reference: 28627629 - Oncol Rep. 2017 Jun 19;:null
– reference: 28055103 - CA Cancer J Clin. 2017 Jan;67(1):7-30
SSID ssj0023259
Score 2.3867958
Snippet The global incidence of thyroid cancer, one of the most common endocrine malignancies, is especially high among women. Although most patients with thyroid...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 312
SubjectTerms Antineoplastic Agents - pharmacology
Apoptosis
Apoptosis - drug effects
Biomarkers
Caspases - metabolism
Cell cycle
Cell Cycle - drug effects
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Transformation, Neoplastic - genetics
Cell Transformation, Neoplastic - metabolism
Flow Cytometry
Humans
Neuroendocrine tumors
Piperidines - pharmacology
Proto-Oncogene Proteins c-akt - metabolism
Signal Transduction - drug effects
Thyroid cancer
Thyroid Neoplasms - genetics
Thyroid Neoplasms - metabolism
Thyroid Neoplasms - pathology
SummonAdditionalLinks – databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLoryaUiojwQlZXcex45xQtHQpHDi1qLcofkRNtY1Dkj3033eceEMXRC85JM5rxvZ8Mx7Ph9BHVaWloEoRmZQ-dMMVKTkcBNWaLpTRzI4Jsj_F2UXy45JfhoBbH9Iqt3PiOFEbp32M_ARcE7DkMRXiS_ubeNYov7oaKDQeoycULI1P6ZKrb7PDxeKRLA3uoUTwTEyJ7wzc_JP6-qb3thD6dLxrkv7BmX-nS96zP6sX6HkAjjifNL2PHtnmJXo6UUnevkLX3xv8qx46h3O_8XZz4zqc64kaArsK52vXjjv9sGvwGLnH51e3nasNXnrFd3hp1-seB94eOAlTTW_J10CSO-C8de3g-rp_jS5Wp-fLMxJ4FIhOaDyQRCibwVCTVckEZzCvLDLDZaU4T1liNLhci5IxyyTISAuw-ZUwSSlMFQtpq5S9QXuNa-wBwjrNeJoyY5WW8OxYJb5emJFSA_DimYnQ560oCx2KjHuui3UBzoYXfHFf8BH6NLdup-Ia_2l3tNVKEYZYX_zpEBH6MF-GweFXPMrGuk1fUPgz6VcCeYTeTkqcXwQ4B9AboxFKd9Q7N_CFt3evNPXVWIDb798FqHj48Ge9Q88AXflUQRLTI7Q3dBv7HhDMoI7HbnoHk1nwng
  priority: 102
  providerName: ProQuest
Title In Vitro Antitumor Activity of Aloperine on Human Thyroid Cancer Cells through Caspase-Dependent Apoptosis
URI https://www.ncbi.nlm.nih.gov/pubmed/29361731
https://www.proquest.com/docview/2109292166
https://www.proquest.com/docview/1990851695
https://pubmed.ncbi.nlm.nih.gov/PMC5796256
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZKKyQuiHdDy8pIcEKBTRw_ckAoLF0KEhVCXbS3KH5ETZXG2yQrsf-ecZKNuhS4-BA7r5mx5xs_5kPolcx5xgIpfRFlbuqGSj-jULBAqWAqtSKm2yB7xk4X0dclXe6hLdvoIMDmr6Gd45Na1OXbX9ebD9Dh37uIE0L2d8XlVeP8GtgnDMYH4JO44zL4Fo3rCQAbOtq0ALyRz2jM-i3wt-7edU63EOefGydveKL5A3R_gJA46XX-EO2Z6hG625NKbh6jyy8V_lm0tcWJO4K7vrI1TlRPEoFtjpPSrrozf9hWuJvDx-cXm9oWGs-cCdR4ZsqywQODD1yEQacx_qeBLrfFycquWtsUzRO0mJ-cz079gVHBV1EQtn7EpImh04k8I4wSGGGmsaYil5RyEmkFwdc0I8QQATJSDLx_znSUMZ2HTJick6dov7KVOURY8ZhyTrSRSsCzQxm5zGFaCAUQjMbaQ2-2okzVkG7csV6UKYQdTvDpTcF76PXYetWn2fhHu-OtVtKtraQQtQLIC0G5Hno5VkM3cWsfWWXsukkD-DPh1gSph571ShxfBIgHcBwJPMR31Ds2cCm4d2uq4qJLxe1O8gJofP7_zzpC9wBnuU2Dfhgco_22XpsXgGVaOUF3-JJDKeafJ-jg48nZ9x8T513opDPg326h95A
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgQXxLMEChiJnlDUTRw7yQGhaMuyS0tPW9RbiB1HTbWNQ5IV2j_Fb2ScF10Q3HrJIZk4jj3jmbFn5gN4KzI_4Y4QduAlZuuGCTtheOGOlM5EpJKqNkD2lM_PvM_n7HwHfg65MCasclgT24U61dLskR-ia4Ka3HU4_1B-tw1qlDldHSA0OrY4Vpsf6LLV7xdHOL8Hrjv7uJzO7R5VwJae4za2x4UKkfGCLKGcUZSySZiyIBOM-dRLJTogk4RSRQMWcslRA2Y89RKeZi4PVOZTbPcW3PYoanKTmT77NDp41G3B2bCPjs3x7S7QHgknh_nlVW10L8qQu60C_7Jr_wzPvKbvZg_gfm-okqjjrIewo4pHcKeDrtw8hstFQb7mTaVJZBJ911e6IpHsoCiIzki00mWbWUh0QdqTArK82FQ6T8nUMFpFpmq1qkmPE4Q3cWmrlX3Ug_I2JCp12eg6r5_A2Y2M8FPYLXShngGRfsh8n6ZKyADbdoVn6pOlQSDR0GNhasG7YShj2Rc1N9gaqxidGzPw8fWBt-BgpC67Yh7_oNsfZiXuRbqOfzOgBW_GxyiM5oQlKZRe17GDfxaYk0dmwV43ieOH0K5Ca5E6Fvhb0zsSmELf20-K_KIt-G3yhdE0ff7_br2Gu_Pll5P4ZHF6_ALuoWVnwhRt19mH3aZaq5doPTXiVcuyBL7dtIz8AuMOK9M
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrUBcKt6kFDASPaFoN3HsJAeEwm5XXYpWFWpRbyFxHDXVNg5JVmj_Gr-OcV50QXDrJYfEcZzxjGfGM54P4G2cuhG34tj0nEhv3bDYjBheuCWENYkTQWWTILvkx-fOpwt2sQM_-7MwOq2yXxObhTpRQu-Rj9E1QU1uW5yP0y4t4nQ2_1B8NzWClI609nAaLYucyM0PdN-q94sZzvWhbc-PzqbHZocwYArHsmvT4bH0kQm9NKKcUZS4iZ8wL40Zc6mTCHRGJhGlknrM54KjNkx54kQ8SW3uydSl2O8d2HW1VzSC3Y9Hy9Mvg7tH7QaqDUdsmRzfb9PuKfUn4-zqutKaGCXK3laIf1m5fyZr3tB-8wew15mtJGj57CHsyPwR3G2BLDeP4WqRk69ZXSoS6GO_62tVkkC0wBREpSRYqaI5Z0hUTpq4ATm73JQqS8hUs11JpnK1qkiHGoQ3caGrpDnrIHprEhSqqFWVVU_g_FZo_BRGucrlcyDC9Znr0kTGwsO-7djR1coSzxNo9jE_MeBdT8pQdCXONdLGKkRXRxM-vEl4Aw6H1kVb2uMf7Q76WQk7Aa_C3-xowJvhMYqmjrdEuVTrKrTwzzwdh2QGPGsncfgQWlloO1LLAHdreocGuuz39pM8u2zKf-vTw2io7v9_WK_hHspH-HmxPHkB99HM0zmLpm0dwKgu1_IlmlJ1_KrjWQLfbltMfgHVTjFl
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+Vitro+Antitumor+Activity+of+Aloperine+on+Human+Thyroid+Cancer+Cells+through+Caspase-Dependent+Apoptosis&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Ying-Ray%2C+Lee&rft.au=Shu-Hsin%2C+Chen&rft.au=Ching-Yen%2C+Lin&rft.au=Wen-Ying%2C+Chao&rft.date=2018-01-21&rft.pub=MDPI+AG&rft.issn=1661-6596&rft.eissn=1422-0067&rft.volume=19&rft.issue=1&rft.spage=312&rft_id=info:doi/10.3390%2Fijms19010312&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon